Sanofi India Peer Comparison

NSE: SANOFI | BSE: 500674

₹3,181.60

₹0.60 (0.02%)

As on 28-Aug-2026IST

Market cap

₹7,326 Cr

Revenue (TTM)

₹1,805 Cr

P/E Ratio

22.6

P/B Ratio

8.9

Div. Yield

3.9 %

Edit

	Sanofi India	JB Chemicals	Pfizer	Caplin Point Lab	Eris Lifesciences
Market cap (₹ Cr)	7,326	38,731	21,501	19,125	18,253
Revenue (₹ Cr)	1,805	4,148	2,570	2,287	3,230
Net Profit (₹ Cr)	323.80	709.47	735.15	678.07	666.92
Net Margin (%)	17.76	16.85	26.88	28.10	20.60
RoE (%)	43.69	19.11	19.16	19.73	18.75
Price to Earnings	22.62	54.59	29.25	28.74	28.35
Price-To-Book	8.87	9.31	4.88	5.08	4.51

Income Statement (₹ Cr)

	Sanofi India	JB Chemicals	Pfizer	Caplin Point Lab	Eris Lifesciences
Operating Revenue	1,837.40	3,917.99	2,281.35	1,937.47	2,893.64
Total Income	1,857.10	3,957.03	2,453.60	2,033.90	2,912.00
Total Expenditure	1,346.10	2,886.87	1,541.03	1,290.54	1,876.44
EBITDA	491.30	1,031.12	740.32	646.93	1,017.20
Depreciation	37.30	171.04	60.79	65.96	315.46
EBIT	454.00	860.08	679.53	580.97	701.74
Interest	1.70	11.73	8.50	0.61	231.29
Other Income	19.70	39.04	172.25	96.43	18.36
Exceptional Items	-27.30	--	172.81	--	--
Profit before Tax	444.70	887.39	1,016.09	676.78	488.87
Provision for Tax	118.00	227.81	248.49	135.69	114.20
Profit after Tax	326.70	659.58	767.60	541.09	374.67

	Sanofi India	JB Chemicals	Pfizer	Caplin Point Lab	Eris Lifesciences
Shareholder's Funds	749.20	3,433.32	4,217.41	2,850.49	2,854.36
Minority Interest	--	--	--	35.90	417.40
Non-Current Liabilities	1,159.50	443.23	54.89	13.24	2,100.97
Current Liabilities	2,514.20	1,156.93	569.51	305.99	1,489.55
Total Liabilities	4,427.30	5,033.48	4,911.11	3,207.85	6,862.28

	Sanofi India	JB Chemicals	Pfizer	Caplin Point Lab	Eris Lifesciences
Non-Current Assets	1,599.50	2,586.15	1,328.96	1,071.67	5,531.13
Current Assets	2,823.40	2,447.33	3,512.85	2,133.95	1,331.15
Total Assets	4,427.30	5,033.48	4,911.11	3,207.85	6,862.28
Total Debt*	0.00	13.80	2.50	0.55	2,421.66
Net Current Assets	309.20	1,290.40	2,943.34	1,827.96	-158.40
Contingent Liabilities	318.60	131.94	363.79	0.64	64.29

	Sanofi India	JB Chemicals	Pfizer	Caplin Point Lab	Eris Lifesciences
Cash From Operating Activities	438.30	902.45	659.75	432.37	1,065.01
Cash Flow from Investing Activities	-11.30	-295.90	-71.34	-334.73	-79.97
Cash from Financing Activities	-447.90	-579.67	-205.34	-38.32	-881.32
Net Cash Inflow / Outflow	-20.90	26.88	383.07	59.32	103.72

	Sanofi India	JB Chemicals	Pfizer	Caplin Point Lab	Eris Lifesciences
ROCE (%)	55.46	26.73	26.21	26.22	13.59
ROE (%)	44.50	21.81	19.65	21.72	13.81
ROA (%)	7.18	13.58	17.03	18.37	5.48
EBIT Margin (%)	27.81	27.31	40.00	38.37	35.79
Net Margin (%)	17.59	16.67	31.28	26.60	12.87
Cash Profit Margin (%)	17.51	20.46	34.70	31.33	23.22

	Sanofi India	JB Chemicals	Pfizer	Caplin Point Lab	Eris Lifesciences
Revenue Growth (%)	-8.73	12.45	4.02	14.37	44.02
EBIT Growth (%)	0.73	14.56	11.86	20.21	48.22
Net Profit Growth (%)	4.14	19.35	39.23	17.27	-5.65
EPS Growth (%)	4.14	18.98	39.23	17.25	-10.39
Book Value Growth (%)	-14.39	17.31	17.30	23.77	10.19

	Sanofi India	JB Chemicals	Pfizer	Caplin Point Lab	Eris Lifesciences
Price / Earnings	28.81	38.29	23.86	28.38	54.83
Price / Book Value	13.89	7.73	4.34	5.52	6.78
Dividend Yield (%)	3.01	0.96	4.12	0.30	0.52
EV/EBITDA	17.88	23.49	17.01	19.78	20.75
Market Cap (₹ Cr)	9,410.98	25,253.79	18,318.10	15,219.80	19,292.77

	Sanofi India	JB Chemicals	Pfizer	Caplin Point Lab	Eris Lifesciences
Debt to Equity	0.00	0.00	0.00	0.00	0.85
Short term debt to equity ratio	--	0.00	0.00	0.00	0.14
Current Ratio	1.12	2.12	6.17	6.97	0.89
Quick Ratio	1.00	1.66	5.33	5.88	0.67
Interest Coverage	262.59	76.66	120.54	1,110.48	3.11

	Sanofi India	JB Chemicals	Pfizer	Caplin Point Lab	Eris Lifesciences
Debtors to sales (%)	9.62	20.81	8.46	32.65	15.85
Asset Turnover	0.46	0.84	0.53	0.66	0.43
Receivable days	35.69	67.54	29.10	110.70	54.07
Inventory Days	71.21	46.37	69.53	65.86	32.16
Payable days	122.11	106.33	76.77	105.88	140.91
Cash Conversion Cycle	-15.20	7.58	21.86	70.68	-54.68

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.